Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma
NCT04380545Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2021
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in fibrolamellar hepatocellular carcinoma (FLHCC), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2021; status: active, not recruiting.
02
Drugs
03
Conditions
fibrolamellar hepatocellular carcinoma (FLHCC)
Beyond the preview
Go deeper on NCT04380545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380545.